Moderna (MRNA) Total Non-Current Liabilities (2017 - 2026)

Moderna (MRNA) has 10 years of Total Non-Current Liabilities data on file, last reported at $3.8 billion in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 60.62% year-over-year to $3.8 billion in Q1 2026; TTM through Mar 2026 was $3.8 billion, a 60.62% increase from a year earlier, with the FY2025 full-year figure at $3.4 billion, up 14.43% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $3.8 billion, up from $3.4 billion in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for MRNA reached as high as $10.4 billion in Q1 2022 and fell as low as $2.3 billion in Q2 2025.
• Historically, Total Non-Current Liabilities has averaged $4.8 billion across 5 years, with a median of $3.8 billion in 2026.
• Across the five-year window, Total Non-Current Liabilities slumped 51.17% in 2023 and soared 60.62% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $6.6 billion in 2022, then tumbled by 34.61% to $4.3 billion in 2023, then sank by 31.09% to $3.0 billion in 2024, then increased by 14.43% to $3.4 billion in 2025, then grew by 11.58% to $3.8 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $3.8 billion in Q1 2026, $3.4 billion in Q4 2025, and $2.5 billion in Q3 2025.